Expert Ratings For OrthoPediatrics
Portfolio Pulse from Benzinga Insights
OrthoPediatrics (NASDAQ:KIDS) has received mixed analyst ratings over the past quarter, with a recent positive shift in the 12-month price target to $40.29, up 20.88% from $33.33. Analysts from firms like Needham, JMP Securities, and Truist Securities have updated their ratings and price targets, reflecting a bullish to indifferent sentiment. The company, specializing in pediatric orthopedic devices, shows a positive revenue trend with a growth rate of 21.36% as of December 31, 2023, but struggles with profitability, having a net margin of -17.79%. Despite this, its ROE and prudent debt management indicate strong financial performance and a balanced approach to debt.
May 07, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OrthoPediatrics has seen a positive shift in analyst sentiment, with an updated average 12-month price target of $40.29, indicating a bullish outlook. The company's strong revenue growth and financial performance metrics, despite a negative net margin, suggest potential for stock appreciation.
The increase in the average price target by analysts, coupled with OrthoPediatrics' significant revenue growth and effective use of equity, suggests a positive short-term impact on its stock price. The mixed analyst ratings reflect a cautious optimism, but the overall upward revision in price targets and positive financial indicators support a likely appreciation in stock value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100